Tag: Lipodystrophy

Clinical trials indicate that a specific daily dose of tesamorelin can lead to a notable reduction in visceral adipose tissue (VAT) over several months. This often leads to questions about the effectiveness of lower doses, such as 1 mg, for achieving comparable outcomes.

In clinical trials, tesamorelin has been shown to decrease visceral adipose tissue (VAT) by approximately 15% to 20% in patients with HIV-associated lipodystrophy over 26 to 52 weeks. But beyond this specific application, does tesamorelin burn belly fat for the general population seeking weight loss, and how does it work?

While both Tesamorelin and Sermorelin act as growth hormone-releasing hormone (GHRH) analogs, their potency, therapeutic focus, and cost differ significantly. Understanding these distinctions is key to answering the question: **Is Tesamorelin better than sermorelin?**